64 results about "Cerebral cancer" patented technology

The invention discloses a traditional Chinese patent medicine with the components of plant polysaccharide and bamboo extract for treating medium and terminal cancer, which has a formula as follow: 10 kg of whangee, 5 kg of CV.Ventricousinternode, 10 kg of moso bamboo, 5 kg of palm bamboo, 5 kg of phyllostachys glauca, 10 kg of fishscale bamboo and 5 kg of fortune paulownia bark. A method for preparing the traditional Chinese patent medicine comprises the following steps: adding 50 kg of water into the total 50 kg of the medical materials; decocting the mixture to obtain 200 ml to 400ml of concentrated material; adding mineral trace elements: 0.01 milligrams of calcium, 0.01 milligrams of ferrum, 0.01 milligrams of zinc, 0.01 milligrams of selenium, 0.01 milligrams of iodine and 0.01 milligrams of potassium which are essential to the body into the concentrated material after removing impurities and filtering; finally, fermenting the final mixture to obtain the medicine, and bottling the medicine for use. The traditional Chinese patent medicine has the beneficial effects of treating medium and terminal esophagus cancer, gastric cancer, intestinal cancer, liver cancer, cerebral cancer and other cancers and treating gastritis, gastric ulcer, hepatitis, rhinitis and other inflammation. In addition, the traditional Chinese patent medicine can be also used for treating skin cancer and various kinds of skin diseases by exterior spreading. The traditional Chinese patent medicine takes effect rapidly and has no toxic and side effect.

The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1 / CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer.

The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.

Nanoparticle having a crosslinked chitosan-polyethylene oxide oligomer copolymer coating to which O6-benzylguanine is covalently coupled, compositions that include the nanoparticle, and methods for using the nanoparticle to treat brain cancers.

The invention discloses a Ras and HDAC dual inhibitor as well as a preparation method and an application thereof. The Ras and HDAC dual inhibitor has a structure of general formulas I and II and can be used for preparing a medicine for treating chronic inflammation and treating tumors of liver cancer, pancreatic cancer, lung cancer, breast cancer, cerebral cancer, colon cancer and stomach cancer.

The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The invention relates to a Chinese traditional medicine composition for treating cancers. The Chinese traditional medicine composition is prepared from, by weight, 25-35 parts of ganoderma lucidum, 10-20 parts of ganoderma multiplicatum, 15-25 parts of lycopi herba, 5-15 parts of scutellariae barbatae herba, 5-15 parts of echinacea purpurea herb extractive, 3-7 parts of ginseng, 3-7 parts of curcumae rhizome and 3-7 parts of herba hedyotidis. The Chinese traditional medicine composition for treating the cancer is a broad spectrum anti-cancer medicine, is applied to liver cancer, stomach cancer, lung cancer, pancreatic cancer, rectal cancer, lymph cancer, parotid gland cancer, cerebral cancer, breast cancer, uterine cancer, ovarian cancer, bone cancer, liver embryo sarcoma, thyroid cancer and the like. By tonifying qi and consolidating body resistance, activating blood and removing blood stasis and relieving swelling and pain, the resistance of cancer patients to cancer cells is strengthened, treating both symptoms and root causes is achieved, synergistic anti-infection effects are exerted, the immunity is improved, the anti-cancer effect is increased, the further spreading of the cancer cells of cancer patients in the middle and advanced stage is effectively prevented, the curative effect is significant, and no toxic and side effects occur.

The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.

Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

Methods of treating a subject having a brain tumor comprising (a) administering an oncolytic virus and (b) administering a therapeutic antibody to said subject.

The present invention relates to a pharmaceutical composition for inhibiting growth of cancer stem cells, containing an aldehyde inhibitor and a biguanide-based compound. The pharmaceutical composition according to the present invention contains a combination of an aldehyde inhibitor and a biguanide-based compound, which can effectively inhibit the growth of cancer stem cells such as neurospheres and can also inhibit the proliferation, invasion and metastasis of cancer cells, thereby preventing and / or treating cancer such as brain cancer.

The invention discloses a Ras and HDAC dual inhibitor as well as a preparation method and an application thereof. The Ras and HDAC dual inhibitor has a structure of general formulas I and II and can be used for preparing a medicine for treating chronic inflammation and treating tumors of liver cancer, pancreatic cancer, lung cancer, breast cancer, cerebral cancer, colon cancer and stomach cancer.

A method of treating brain cancer in an immune-competent human patient by administering ternozolornide to the immune-competent human patient, the improvement comprising administering to said immune-competent human patient a viral vector.